Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.75 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.75 |
| ▸ | ITGAV | P06756 | 16/20 | 0.73 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.72 |
| ▸ | ITGA5 | P08648 | 6/20 | 0.71 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464836 | 1.00 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL31294830 | 0.96 | ITGB3 (0.80) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL29366713 | 0.92 | ITGB3 (0.74) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL17364341 | 0.92 | ITGB3 (0.74) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL30098352 | 0.90 | ITGB3 (0.76) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Cyclorgdfv SCHEMBL30636069 | 0.89 | ITGB3 (0.78) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Cyclorgdfv SCHEMBL29384091 | 0.89 | ITGB3 (0.78) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Trifluoroacetic Acid SCHEMBL20917265 | 0.87 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Trifluoroacetic Acid SCHEMBL29992576 | 0.87 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL29853738 | 0.85 | ITGB3 (0.74) | ITGB3ITGA2BITGAVITGB5ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120037403-A | Preparation method of ROS response drug-loaded double-targeting nano delivery system for treating diabetic nephropathy | 浙江大学医学院附属邵逸夫医院 | 2025-05-27 | — | — | CN | claimed |
| CN-119112903-A | Nanometer preparation for regulating mechanical microenvironment of idiopathic pulmonary fibrosis and preparation method and application thereof | 中国药科大学 | 2024-12-13 | — | — | CN | claimed |
| CN-118731249-A | Simultaneous separation and determination method for terminal modified decafluorobiphenyl polypeptide drug and related substances thereof | 无锡学院 | 2024-10-01 | — | — | CN | claimed |
| US-20240238383-A1 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | UNIV OF LOWA RESEARCH FOUNDATION (US) | 2024-07-18 | — | — | US | claimed |
| EP-4340894-A1 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | University Of Iowa Research Foundation (US) | 2024-03-27 | — | — | EP | claimed |
| WO-2022246280-A1 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2022-11-24 | — | — | WO | claimed |
| US-20260102508-A1 | ARRDC1-Mediated Microvesicle-Based Delivery of Therapeutic Agents to Cells and Tissues of the Eye | TURN BIOTECHNOLOGIES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12584112-B2 | Organoid tissue engineering | Ecolepol Ytechnique Federale de Lausanne (CH) | 2026-03-24 | — | — | US | disclosed |
| EP-4680617-A1 | ARRDC1-MEDIATED MICROVESICLE-BASED DELIVERY OF RNA-GUIDED PROTEINS | Turn Biotechnologies, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4593805-A2 | ARRDC1-MEDIATED MICROVESICLE-BASED DELIVERY OF THERAPEUTIC AGENTS TO CELLS AND TISSUES OF THE EYE | Turn Biotechnologies, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-120037403-A | Preparation method of ROS response drug-loaded double-targeting nano delivery system for treating diabetic nephropathy | 浙江大学医学院附属邵逸夫医院 | 2025-05-27 | — | — | CN | disclosed |
| CN-119112903-A | Nanometer preparation for regulating mechanical microenvironment of idiopathic pulmonary fibrosis and preparation method and application thereof | 中国药科大学 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024238808-A2 | ARRDC1-MEDIATED MICROVESICLE-BASED INFLAMMATION MODULATION | Vesigen, Inc. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20230043948-A1 | METHOD AND KIT FOR CELL GROWTH | Precision Cancer Technologies Inc . (CA) | 2023-02-09 | — | — | US | disclosed |
| EP-4069823-A1 | METHOD AND KIT FOR CELL GROWTH | Precision Cancer Technologies Inc. (CA) | 2022-10-12 | — | — | EP | disclosed |
| US-20220288229-A1 | TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-09-15 | — | — | US | disclosed |
| US-20220235316-A1 | Novel Hydrogels | LEIBNIZ-INSTITUT FÜR NEUE MATERIALIEN GEMEINNÜTZIGE GMBH (DE) | 2022-07-28 | — | — | US | disclosed |
| US-20220177494-A1 | pH-RESPONSIVE SILICA METAL ORGANIC FRAMEWORK NANOPARTICLES FOR DELIVERY OF BIOACTIVE MOLECULES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-06-09 | — | — | US | disclosed |
| US-11351263-B2 | Polyplex delivery system for proteins, nucleic acids and protein/nucleic acid complexes | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-06-07 | — | — | US | disclosed |
| EP-3994202-A1 | NOVEL HYDROGELS | Leibniz-Institut für Neue Materialien gemeinnützige GmbH (DE) | 2022-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351263-B2 | Polyplex delivery system for proteins, nucleic acids and protein/nucleic acid complexes | PABPC1, PABPC4, PCNP | ITGB3 3283/4885ITGA2B 3998/4885ITGAV 3142/4885 |
| US-12584112-B2 | Organoid tissue engineering | KIT, EPCAM, ALPG | ITGB3 19/4885ITGA2B 65/4885ITGAV 313/4885 |
| US-20220288229-A1 | TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF | CD47, CD44, FURIN | ITGB3 453/4885ITGA2B 229/4885ITGAV 127/4885 |
| US-20260102508-A1 | ARRDC1-Mediated Microvesicle-Based Delivery of Therapeutic Agents to Cells and Tissues of the Eye | EXOSC4, EXOSC5, ARRB1 | ITGB3 827/4885ITGA2B 911/4885ITGAV 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.